Protection from experimental autoimmune thyroiditis in CBA mice with the novel immunosuppressant deoxyspergualin

F. Nicoletti, R. Di Marco, W. Barcellini, M. O. Borghi, M. Lunetta, L. Mughini, P. L. Meroni

Research output: Contribution to journalArticle

Abstract

The effects of the novel immunosuppressant Deoxyspergualin (DSP) on the development of experimental autoimmune thyroiditis (EAT) in CBA mice were studied. For EAT induction, the mice were immunized with 100 μg of porcine thyroglobulin (p Tg) emulsified in CFA on day 0 and in IFA, for boosting, on day 14. Twenty-eight days after primary immunization, histological and serological signs of EAT occurred in control mice treated with PBS which showed marked lymphoid infiltration of the thyroid glands along with increased serum titres of anti-pTg antibodies. Development of both these EAT features was significantly suppressed when the mice were treated with 2.5 mg/kg body weight DSP, given daily, five times a week, from day -2 to day +28 after immunization. The effect appeared to be dose-dependent and DSP was ineffective when given under the same experimental conditions at the dose of 0.5 mg/kg body weight. No DSP-toxic effects could be observed during the experiment. These results provide further evidence for the powerful immunosuppressive properties of DSP and suggest that this drug may be used in the treatment of autoimmune thyroid diseases and other T-cell mediated autoimmune disorders in humans.

Original languageEnglish
Pages (from-to)333-336
Number of pages4
JournalScandinavian Journal of Immunology
Volume39
Issue number3
DOIs
Publication statusPublished - 1994

Fingerprint

Autoimmune Thyroiditis
Inbred CBA Mouse
Immunosuppressive Agents
Immunization
Body Weight
Thyroglobulin
Poisons
Thyroid Diseases
Autoimmune Diseases
Anti-Idiotypic Antibodies
Thyroid Gland
Swine
gusperimus
T-Lymphocytes
Serum
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology

Cite this

Protection from experimental autoimmune thyroiditis in CBA mice with the novel immunosuppressant deoxyspergualin. / Nicoletti, F.; Di Marco, R.; Barcellini, W.; Borghi, M. O.; Lunetta, M.; Mughini, L.; Meroni, P. L.

In: Scandinavian Journal of Immunology, Vol. 39, No. 3, 1994, p. 333-336.

Research output: Contribution to journalArticle

@article{e9edf17ac4da4a348a45db0815970270,
title = "Protection from experimental autoimmune thyroiditis in CBA mice with the novel immunosuppressant deoxyspergualin",
abstract = "The effects of the novel immunosuppressant Deoxyspergualin (DSP) on the development of experimental autoimmune thyroiditis (EAT) in CBA mice were studied. For EAT induction, the mice were immunized with 100 μg of porcine thyroglobulin (p Tg) emulsified in CFA on day 0 and in IFA, for boosting, on day 14. Twenty-eight days after primary immunization, histological and serological signs of EAT occurred in control mice treated with PBS which showed marked lymphoid infiltration of the thyroid glands along with increased serum titres of anti-pTg antibodies. Development of both these EAT features was significantly suppressed when the mice were treated with 2.5 mg/kg body weight DSP, given daily, five times a week, from day -2 to day +28 after immunization. The effect appeared to be dose-dependent and DSP was ineffective when given under the same experimental conditions at the dose of 0.5 mg/kg body weight. No DSP-toxic effects could be observed during the experiment. These results provide further evidence for the powerful immunosuppressive properties of DSP and suggest that this drug may be used in the treatment of autoimmune thyroid diseases and other T-cell mediated autoimmune disorders in humans.",
author = "F. Nicoletti and {Di Marco}, R. and W. Barcellini and Borghi, {M. O.} and M. Lunetta and L. Mughini and Meroni, {P. L.}",
year = "1994",
doi = "10.1111/j.1365-3083.1994.tb03380.x",
language = "English",
volume = "39",
pages = "333--336",
journal = "Scandinavian Journal of Immunology",
issn = "0300-9475",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Protection from experimental autoimmune thyroiditis in CBA mice with the novel immunosuppressant deoxyspergualin

AU - Nicoletti, F.

AU - Di Marco, R.

AU - Barcellini, W.

AU - Borghi, M. O.

AU - Lunetta, M.

AU - Mughini, L.

AU - Meroni, P. L.

PY - 1994

Y1 - 1994

N2 - The effects of the novel immunosuppressant Deoxyspergualin (DSP) on the development of experimental autoimmune thyroiditis (EAT) in CBA mice were studied. For EAT induction, the mice were immunized with 100 μg of porcine thyroglobulin (p Tg) emulsified in CFA on day 0 and in IFA, for boosting, on day 14. Twenty-eight days after primary immunization, histological and serological signs of EAT occurred in control mice treated with PBS which showed marked lymphoid infiltration of the thyroid glands along with increased serum titres of anti-pTg antibodies. Development of both these EAT features was significantly suppressed when the mice were treated with 2.5 mg/kg body weight DSP, given daily, five times a week, from day -2 to day +28 after immunization. The effect appeared to be dose-dependent and DSP was ineffective when given under the same experimental conditions at the dose of 0.5 mg/kg body weight. No DSP-toxic effects could be observed during the experiment. These results provide further evidence for the powerful immunosuppressive properties of DSP and suggest that this drug may be used in the treatment of autoimmune thyroid diseases and other T-cell mediated autoimmune disorders in humans.

AB - The effects of the novel immunosuppressant Deoxyspergualin (DSP) on the development of experimental autoimmune thyroiditis (EAT) in CBA mice were studied. For EAT induction, the mice were immunized with 100 μg of porcine thyroglobulin (p Tg) emulsified in CFA on day 0 and in IFA, for boosting, on day 14. Twenty-eight days after primary immunization, histological and serological signs of EAT occurred in control mice treated with PBS which showed marked lymphoid infiltration of the thyroid glands along with increased serum titres of anti-pTg antibodies. Development of both these EAT features was significantly suppressed when the mice were treated with 2.5 mg/kg body weight DSP, given daily, five times a week, from day -2 to day +28 after immunization. The effect appeared to be dose-dependent and DSP was ineffective when given under the same experimental conditions at the dose of 0.5 mg/kg body weight. No DSP-toxic effects could be observed during the experiment. These results provide further evidence for the powerful immunosuppressive properties of DSP and suggest that this drug may be used in the treatment of autoimmune thyroid diseases and other T-cell mediated autoimmune disorders in humans.

UR - http://www.scopus.com/inward/record.url?scp=0028275558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028275558&partnerID=8YFLogxK

U2 - 10.1111/j.1365-3083.1994.tb03380.x

DO - 10.1111/j.1365-3083.1994.tb03380.x

M3 - Article

C2 - 8128193

AN - SCOPUS:0028275558

VL - 39

SP - 333

EP - 336

JO - Scandinavian Journal of Immunology

JF - Scandinavian Journal of Immunology

SN - 0300-9475

IS - 3

ER -